chemXplore
Product Pricing About Us
Sign in

Swedish Orphan Biovitrum AB

Swedensobi.com

Swedish Orphan Biovitrum AB (Sobi) is an international biopharmaceutical company specializing in rare diseases, headquartered in Stockholm, Sweden.

Also known as Swedish Orphan Biovitrum.

Latest news on Sobi

24 August 2026
Sobi Japan and Asahi Kasei: Empaveli approved in Japan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis

First complement inhibitor in Japan for patients aged 12+ with these rare kidney diseases; VALIANT showed 68.1% proteinuria reduction and eGFR stabilization versus placebo.